Skip to main content
OpenTrials
Completed

NCT Number: NCT00661635

A Randomized, Double-Blind Study of the Efficacy and Safety of Valdecoxib Compared to Placebo for Treatment of Post- Cholecystectomy Surgery Pain

To evaluate the analgesic efficacy, general safety, and effects on health outcome measures and opioid-related symptoms of 2 valdecoxib dosing regimens compared with placebo in patients with moderate or severe pain following laparoscopic cholecystectomy surgery.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–75 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 3

Primary location

Pfizer Investigational Site, Birmingham, Alabama, United States

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients had required an elective, non-urgent laparoscopic cholecystectomy, as an outpatient procedure, with ASA Class I-III, with a Baseline Pain Intensity of moderate or severe on a categorical scale and ≥45 mm on a VAS (100 mm)
  • Patients were able to get their first dose of study medication within 8 hours after the end of surgery

Exclusion criteria

  • Patients could not undergo procedures expected to produce a greater degree of surgical trauma than the laparoscopic cholecystectomy alone, nor have acute pre-operative pain (other than biliary colic) nor chronic pain conditions, nor uncontrolled chronic conditions, nor cancer, nor a laboratory abnormality that the investigator considered to contraindicate study participation
  • Patient had any cognitive impairment that would, in the investigator's opinion, preclude study participation or compliance with protocol mandated procedures
  • Patient had a history of known alcohol, analgesic, or narcotic substance abuse within the one year prior to Screening
  • Patient had any laboratory abnormality at screening, that, in the opinion of the investigator, is not due to the condition requiring surgery and is not expected to resolve post-surgery, and would, therefore, contraindicate study participation

Treatment and study plan

Placebo

Drug

valdecoxib 40 mg by mouth within 8 hours after the end of surgery, followed by a second dose of valdecoxib 20 mg within 1 to 12 hours (or by midnight on the Day 1, whichever was earlier); then, placebo twice daily (BID) on Days 2 to 5

valdecoxib

Drug

valdecoxib 40 mg by mouth within 8 hours after the end of surgery, followed by a second dose of valdecoxib 20 mg within 1 to 12 hours (or by midnight on the Day 1, whichever was earlier); then, valdecoxib 20 mg once daily (QD)on Days 2 to 5.

Primary outcomes

  1. Patient's Global Evaluation of Study Medication

    Time frame: Day 2 and Day 3

  2. Summed Pain Intensity (categorical) through 24 hours (SPI 24)

    Time frame: Day 2 and Day 3

Secondary outcomes

  1. Time-specific PI (VAS)

    Time frame: Days 2 to 5

  2. Patient's Global Evaluation of Study Medication

    Time frame: Day 4 and Day 5

  3. Time to first dose of rescue medication

    Time frame: Days 2 to 5

  4. Percent of patients who took rescue medication on each study day

    Time frame: Days 2 to 5

  5. Amount of rescue medication taken

    Time frame: Days 2 to 5

  6. Time between doses of study medication

    Time frame: Days 2 to 5

  7. Worst PI (derived from the mBPI-SF)

    Time frame: Days 2 to 5

  8. Average PI (derived from the mBPI-SF)

    Time frame: Days 2 to 5

  9. SPI 24 (categorical)

    Time frame: Day 4 and Day 5

  10. Time-specific PI (categorical)

    Time frame: Days 2 to 5

  11. SPI 24 (VAS)

    Time frame: Days 2 to 5

Sponsors and collaborators

Lead sponsor

Pfizer

Industry

Registry information

Official study title

A Multiple-Dose, Randomized, Double-Blind, Placebo-Controlled Study of the Analgesic Efficacy and Safety of Valdecoxib Compared to Placebo in Patients for Treatment of Post-Surgical Pain From Laparoscopic Cholecystectomy Surgery

Important dates

Study start
2002
Study completion
2003
First posted
Apr 18, 2008
Registry last updated
Apr 23, 2008

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.